Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Tocilizumab Real-Life Human Factors (RLHFs) Validation Study

ClinicalTrials.gov ID: NCT02682823

Public ClinicalTrials.gov record NCT02682823. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Tocilizumab Real-Life Human Factors Validation Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is designed to evaluate RLHFs concerning administration of the tocilizumab autoinjector AI-1000 G2 in adults with rheumatoid arthritis (RA) who have been receiving subcutaneous (SC) tocilizumab using the commercially available prefilled syringe and needle safety device (PFS-NSD). The study will enroll participants with RA, a subset of whom will be assigned to perform self-injection with the AI-1000 G2. Enrolled caregivers (CGs) and healthcare professionals (HCPs) will administer the AI-1000 G2 injection to the remaining study participants.

Study identification

NCT ID
NCT02682823
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
91 participants

Conditions and interventions

Interventions

Device · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 20, 2016
Primary completion
Jul 28, 2016
Completion
Jul 28, 2016
Last update posted
Apr 18, 2019

2016

United States locations

U.S. sites
8
U.S. states
6
U.S. cities
8
Facility City State ZIP Site status
Arizona Arthritis and Rheuma Mesa Arizona 85202
Valerius Medical Group & Research Ctr of Greater Long Beach Los Alamitos California 90720
Pacific Arthritis Ctr Med Grp Santa Maria California 93454
Bluegrass Comm Research, Inc. Lexington Kentucky 40515
Oklahoma Center For Arthritis Therapy & Research Tulsa Oklahoma 74104
Altoona Center For Clinical Research Duncansville Pennsylvania 16635
Advanced Rheumatology & Arthritis Research Center Wexford Pennsylvania 15090
Metroplex Clinical Research Dallas Texas 75231

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02682823, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 18, 2019 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02682823 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →